Cargando…
Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis
Kirsten rat sarcoma viral oncogene homolog (KRAS) gene encodes a GTPase that acts as a molecular switch for intracellular signal transduction, promoting cell growth and proliferation. Mutations in the KRAS gene represent important biomarkers for NSCLC targeted therapy. However, detection of KRAS mut...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640997/ https://www.ncbi.nlm.nih.gov/pubmed/36386815 http://dx.doi.org/10.3389/fgene.2022.1015161 |
_version_ | 1784825992894742528 |
---|---|
author | Palmieri, Maria Zulato, Elisabetta Wahl, Sissel Gyrid Freim Guibert, Nicolas Frullanti, Elisa |
author_facet | Palmieri, Maria Zulato, Elisabetta Wahl, Sissel Gyrid Freim Guibert, Nicolas Frullanti, Elisa |
author_sort | Palmieri, Maria |
collection | PubMed |
description | Kirsten rat sarcoma viral oncogene homolog (KRAS) gene encodes a GTPase that acts as a molecular switch for intracellular signal transduction, promoting cell growth and proliferation. Mutations in the KRAS gene represent important biomarkers for NSCLC targeted therapy. However, detection of KRAS mutations in tissues has shown some limitations. During the last years, analyses of circulating free DNA (cfDNA) has emerged as an alternative and minimally invasive, approach to investigate tumor molecular changes. Here, we assessed the diagnostic performance of cfDNA analysis, compared to tissues through a meta-analysis and systematic review of existing literature. From 561 candidate papers, we finally identified 40 studies, including 2,805 NSCLC patients. We extracted values relating to the number of true-positive, false-positive, false-negative, and true-negative. Pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio, each with 95% CI, were calculated. A summary receiver operating characteristic curve and the area under curve (AUC) were used to evaluate the overall diagnostic performance. The pooled sensitivity was 0.71 (95% CI 0.68–0.74) and the specificity was 0.93 (95% CI 0.92–0.94). The diagnostic odds ratio was 35.24 (95% CI 24.88–49.91) and the area under the curve was 0.92 (SE = 0.094). These results provide evidence that detection of KRAS mutation using cfDNA testing is of adequate diagnostic accuracy thus offering to the clinicians a new promising screening test for NSCLC patients. |
format | Online Article Text |
id | pubmed-9640997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96409972022-11-15 Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis Palmieri, Maria Zulato, Elisabetta Wahl, Sissel Gyrid Freim Guibert, Nicolas Frullanti, Elisa Front Genet Genetics Kirsten rat sarcoma viral oncogene homolog (KRAS) gene encodes a GTPase that acts as a molecular switch for intracellular signal transduction, promoting cell growth and proliferation. Mutations in the KRAS gene represent important biomarkers for NSCLC targeted therapy. However, detection of KRAS mutations in tissues has shown some limitations. During the last years, analyses of circulating free DNA (cfDNA) has emerged as an alternative and minimally invasive, approach to investigate tumor molecular changes. Here, we assessed the diagnostic performance of cfDNA analysis, compared to tissues through a meta-analysis and systematic review of existing literature. From 561 candidate papers, we finally identified 40 studies, including 2,805 NSCLC patients. We extracted values relating to the number of true-positive, false-positive, false-negative, and true-negative. Pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio, each with 95% CI, were calculated. A summary receiver operating characteristic curve and the area under curve (AUC) were used to evaluate the overall diagnostic performance. The pooled sensitivity was 0.71 (95% CI 0.68–0.74) and the specificity was 0.93 (95% CI 0.92–0.94). The diagnostic odds ratio was 35.24 (95% CI 24.88–49.91) and the area under the curve was 0.92 (SE = 0.094). These results provide evidence that detection of KRAS mutation using cfDNA testing is of adequate diagnostic accuracy thus offering to the clinicians a new promising screening test for NSCLC patients. Frontiers Media S.A. 2022-10-25 /pmc/articles/PMC9640997/ /pubmed/36386815 http://dx.doi.org/10.3389/fgene.2022.1015161 Text en Copyright © 2022 Palmieri, Zulato, Wahl, Guibert and Frullanti. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Palmieri, Maria Zulato, Elisabetta Wahl, Sissel Gyrid Freim Guibert, Nicolas Frullanti, Elisa Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis |
title | Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis |
title_full | Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis |
title_fullStr | Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis |
title_full_unstemmed | Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis |
title_short | Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis |
title_sort | diagnostic accuracy of circulating free dna testing for the detection of kras mutations in non-small cell lung cancer: a systematic review and meta-analysis |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640997/ https://www.ncbi.nlm.nih.gov/pubmed/36386815 http://dx.doi.org/10.3389/fgene.2022.1015161 |
work_keys_str_mv | AT palmierimaria diagnosticaccuracyofcirculatingfreednatestingforthedetectionofkrasmutationsinnonsmallcelllungcancerasystematicreviewandmetaanalysis AT zulatoelisabetta diagnosticaccuracyofcirculatingfreednatestingforthedetectionofkrasmutationsinnonsmallcelllungcancerasystematicreviewandmetaanalysis AT wahlsisselgyridfreim diagnosticaccuracyofcirculatingfreednatestingforthedetectionofkrasmutationsinnonsmallcelllungcancerasystematicreviewandmetaanalysis AT guibertnicolas diagnosticaccuracyofcirculatingfreednatestingforthedetectionofkrasmutationsinnonsmallcelllungcancerasystematicreviewandmetaanalysis AT frullantielisa diagnosticaccuracyofcirculatingfreednatestingforthedetectionofkrasmutationsinnonsmallcelllungcancerasystematicreviewandmetaanalysis |